A Study of Stereotactic Body Radiation Therapy and Avelumab Immunotherapy to Treat Malignant Mesothelioma

Full Title

An Efficacy and Safety Study of Avelumab plus SBRT in Malignant Mesothelioma (MPM)

Purpose

There are limited treatment options and no standard of care for patients with mesothelioma that has grown after initial chemotherapy. In this study, researchers are assessing the safety and effectiveness of a targeted form of radiation therapy called stereotactic body radiation therapy (SBRT) combined with an immunotherapy called avelumab to treat pleural and peritoneal mesothelioma that has continued to grow or came back after previous treatment. SBRT delivers high-dose radiation therapy with high accuracy and effectiveness during one to five treatments. Conventional radiation therapy may require more treatments and may not be as effective.

Avelumab is an antibody that works by blocking a protein on tumor cells called PD-L1. Tumor cells make PD-L1 to help them evade being detected by the immune system. By blocking this protein, avelumab may improve the ability of the immune system to destroy a cancer. Avelumab is given intravenously (by vein).

In addition, radiation therapy itself may boost the power of the immune system against mesothelioma, and avelumab may further enhance this effect. The combination of radiation therapy and immunotherapy may be more effective against mesothelioma than either treatment alone.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or persistent malignant pleural or peritoneal mesothelioma that continued to grow or came back after treatment that included a platinum-containing drug and pemetrexed.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Prior immunotherapy is not permitted.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Andreas Rimner at 212-639-6025.

Protocol

17-358

Phase

I/II

Disease Status

Newly Diagnosed

Investigator

Co-Investigators

Diseases